COMP <GO>
PTGX vs CYTK // EV/EBITDA & P/E VALUATION
Protagonist Therapeutics Inc. (NASDAQ) VS. Cytokinetics Incorporated (NASDAQ) • 15-METRIC TALLY: PTGX 9
— CYTK 1
■ METRIC PARITY
LAST: $139.37 (-3.78%) • MKT CAP: $9.37B
valuation
—
LAST: $62.03 (-1.52%) • MKT CAP: $8.76B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTGX VS. CYTK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTGX | CYTK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.70% | -35.00% | +18.30 | PTGX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.60% | -6.08% | +6.68 | PTGX | /fcf-yield <GO> |
| Operating Margin | -6.00% | -60.00% | +54.00 | PTGX | /operating-margins <GO> |
| Net Profit Margin | -5.00% | -60.00% | +55.00 | PTGX | /net-margins <GO> |
| Revenue Growth (YoY) | 0.00% | 180.00% | -180.00 | CYTK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.45 | +25.55 | PTGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | PTGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.7 | 46.0 | +11.70 | PTGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.87 | +0.12 | PTGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 31.0x | 0.00 | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.37B | $8.76B | $615.9M | PTGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTGX REV | CYTK REV | PTGX GROSS % | CYTK GROSS % | PTGX FCF | CYTK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $442.8M | $88.0M | — | — | $56.1M | -$534.8M |
| FY 2024 | $708.0M | $18.5M | — | — | $182.8M | -$399.8M |
| FY 2023 | $262.2M | $7.5M | — | — | -$70.2M | -$414.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTGX // BETA 0.99
CYTK // BETA 0.87